Appetite accomplice: Ghrelin receptor alters dopamine signaling

GHSR1a allosterically modifies DRD2 signaling via a heteromer. Credit: Roy G. Smith, The Scripps Research Institute

New research reveals a fascinating and unexpected molecular partnership within the brain neurons that regulate appetite. The study, published by Cell Press in the January 26 issue of the journal Neuron, resolves a paradox regarding a receptor without its hormone and may lead to more specific therapeutic interventions for obesity and disorders of dopamine signaling.

Ghrelin is an appetite-stimulating hormone produced by the stomach. Although the ghrelin receptor (GHSR1a) is broadly distributed in the brain, ghrelin itself is nearly undetectable there. This intriguing paradox was investigated by Dr. Roy G. Smith, Dr. Andras Kern, and colleagues from The Scripps Research Institute in Florida. "We identified subsets of neurons in the brain that express both GHSR1a and the dopamine receptor subtype-2 (DRD2)," explains Dr. Smith. "Dopamine signaling in the is linked with feeding behavior, and mutations in DRD2 that attenuate dopamine signaling are associated with obesity in humans. We speculated that expression of both receptors in the same neurons might lead to interactions between GHSR1a and DRD2 that modify dopamine signaling."

The researchers showed that when GHSR1a and DRD2 were coexpressed, the receptors physically interacted with one another. Further, the GHSR1a:DRD2 complex was present in native that regulate appetite. When mice were treated with a molecule (cabergoline) that selectively activates DRD2, they exhibited anorexia. Interestingly, the cabergoline-stimulated anorexia did not require but was dependent on GHSR1a and the GHSR1a:DRD2 interaction. These findings suggest that in neurons expressing both GHSR1a and DRD2, GHSR1a alters classical DRD2 dopamine signaling.

"Perhaps most importantly, we showed that a GHSR1a-selective antagonist blocks dopamine signaling in neurons with both DRD2 and GHSR1a, which allows neuronal selective fine-tuning of dopamine signaling because neurons expressing DRD2 alone will be unaffected," concludes Dr. Smith. "This provides exciting opportunities for designing next-generation therapeutics with fewer side effects for both obesity and psychiatric disorders associated with abnormal dopamine signaling."

More information: Kern et al.: “Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism.” Neuron, January 26, 2012.

Related Stories

MicroRNAs play a role in cocaine addiction

Jul 27, 2010

MicroRNAs, already linked to cancer, heart disease and mental disorders such as schizophrenia, may also be involved in addiction. A team of Rockefeller University neuroscientists has shown that a protein that plays a crucial ...

Hormone ghrelin can boost resistance to Parkinson's disease

Nov 25, 2009

Ghrelin, a hormone produced in the stomach, may be used to boost resistance to, or slow, the development of Parkinson's disease, Yale School of Medicine researchers report in a study published in a recent issue of the Journal of ...

Researchers discover possible markers for mental illness

Dec 03, 2007

Researchers have discovered natural genetic differences that might help predict the most effective antipsychotic drugs for particular patients with mental disorders such as schizophrenia, Parkinson’s and drug addiction. ...

Researchers find 'switch' for brain's pleasure pathway

Mar 22, 2006

Amid reports that a drug used to treat Parkinson's disease has caused some patients to become addicted to gambling and sex, University of Pittsburgh researchers have published a study that sheds light on what may have gone ...

Recommended for you

Out of danger: A neural basis for avoiding threats

9 hours ago

Researchers at the RIKEN Brain Science Institute in Japan have identified a key neuronal pathway that makes learning to avoid unpleasant situations possible. Published online in the November 20 issue of Neuron, the wo ...

New approach for treating ALS

15 hours ago

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis. Currently ALS has no ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.